A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis

Journal of the American College of Cardiology

Volumn 41, Issue 2, 2003, Pages 322-329

  Okura, Yuji ^a   Dec, G William ^b   Hare, Joshua M ^c   Kodama, Makoto ^d   Berry, Gerald J ^e   Tazelaar, Henry D ^a   Bailey, Kent R ^a   Cooper Jr , Leslie T ^a  

^a MAYO CLINIC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d NIIGATA UNIVERSITY   (Japan)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOPSY; CLINICAL EXAMINATION; CONTROLLED STUDY; HEART FAILURE; HEART MUSCLE BIOPSY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IDIOPATHIC GIANT CELL MYOCARDITIS; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MYOCARDITIS; PRIORITY JOURNAL; SARCOIDOSIS; TREATMENT OUTCOME;

EID: 0037438712     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02715-8     Document Type: Article

References (22)

1. Felker G, Thompson R, Hare J, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84.
2. Cooper LT, Berry GJ, Shabetai R. Giant cell myocarditis: natural history and treatment. N Engl J Med 1997;336:1860-6.
3. Johnson JB, Jason RS. Sarcoidosis of the heart. Am Heart J 1948;27:246.
4. Tesluk H. Giant cell versus granulomatous myocarditis. Am J Clin Pathol 1956;26:1326-33.
5. Whitehead R. Isolated myocarditis. Br Heart J 1965;27:220-30.
6. Litovsky SH, Burke AP, Virmani MD. Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol 1996;9:1126-34.
7. Davidoff R, Palacios I, Southern J, Fallon JT, Newell J, Dec GW. Giant cell versus lymphocytic myocarditis: a comparison of their clinical features and long-term outcomes. Circulation 1991;83:953-61.
8. Davies MJ, Pomerance A, Teare RD. Idiopathic giant cell myocarditis - a distinctive clinico-pathological entity. Br Heart J 1975;37:192-5.
9. Johns C, Paz H, Kasper E, Baughman K. Myocardial sarcoidosis: course and management. In: Izumi T, editor. Proceedings of the 12th World Congress on Sarcoidosis, Suppl 1. Milano, Italy: Edizioni Bongraf, 1992:231-6.
10. Fleming HA, Bailey SM. Sarcoid heart disease. J Royal Coll Physicians Lond 1981;15:245-6.
11. Johns C, Michelle T. The clinical management of sarcoidosis. Medicine 1999;78:65-111.
12. Sekiguchi M, Yazaki Y, Isobe M, Hiroe M. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther 1996;10:495-510.
13. Cooper LT, Shabetai R. Data on giant cell myocarditis sought for new study. Circulation 1996;93:199.
14. Cooper LT Jr., Shabetai R. Giant cell myocarditis study group (letter). J Am Coll Cardiol 1995;26:301.
15. Cooper LT Jr., Shabetai R. Giant cell myocarditis study group (letter). Am Heart J 1995;130:1312.
16. Cooper LT Jr., Shabetai R. Announcement of multicenter giant-cell myocarditis study (letter). Am J Cardiol 1995;76:640.
17. Cooper LT Jr., Berry GJ, Rizeq M, Schroeder JS. Giant cell myocarditis. J Heart Lung Transplant 1995;14:394-401.
18. Hunninghake G, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis, Vasculitis Diffuse Lung Dis 1999;16:149-73.
19. Okura Y, Yamamoto T, Goto S, et al. Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats. J Mol Cell Cardiol 1997;29:491-502.
20. Moller D, Forman J, Liu M. Enhanced expression of IL-12 associated with TH1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996;156:4952-60.
21. Rothenberg M. Mechanisms of disease: eosinophilia. N Engl J Med 1998;338:1592-600.
22. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001;88:1006-10.